Executive Summary

Schrödinger, Inc. (SDGR) operates in a supply chain characterized by a high degree of concentration among both suppliers and customers, with key relationships heavily weighted toward biopharmaceutical and technology firms. The company's reliance on a small set of partners, particularly those with confirmed supplier and customer relationships, presents both opportunities and risks, particularly in terms of dependency and potential disruption.

Supplier Analysis

Schrödinger, Inc. has 14 confirmed suppliers, with several appearing multiple times, suggesting strategic partnerships or significant dependency. The highest confidence suppliers (0.72) include Structure Therapeutics Inc. (GPCR), Eli Lilly and Company (LLY), Novartis AG (NVSEF), Sanofi (SNYNF), Recursion Pharmaceuticals, Inc. (RXRX), Cadence Design Systems, Inc. (CDNS), and Simulations Plus, Inc. (SLP). These companies are likely critical for drug discovery, computational modeling, and software integration.

  • Structure Therapeutics Inc. (GPCR): A key player in drug discovery, likely providing specialized tools or data essential to Schrödinger's platform.
  • Eli Lilly and Company (LLY), Novartis AG (NVSEF), Sanofi (SNYNF): These global pharmaceutical giants are likely major clients or collaborators, indicating that Schrödinger's offerings are integral to their research and development pipelines.
  • Cadence Design Systems, Inc. (CDNS) and Simulations Plus, Inc. (SLP): These technology firms may provide critical software or simulation tools that underpin Schrödinger's computational platform.

The repeated appearances of these suppliers suggest a high level of reliance, and the confidence scores (all 0.72) indicate that these relationships are inferred rather than confirmed in SEC filings. This concentration risk could be a vulnerability if any of these partners were to discontinue or alter their relationship with Schrödinger.

Customer Analysis

Schrödinger’s customer base includes a mix of named entities and broad categories. The highest confidence customers (0.92) are labeled as “CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-500-000,” “SOFTWARE-CUSTOMERS,” and “BIOPHARMACEUTICAL-COMPANIES.” These categories suggest that Schrödinger’s clients are primarily high-value biopharmaceutical firms and long-term software users.

  • Customer Retention: The company reports a 95% retention rate for customers with an ACV of $100,000 or more and 100% for those with ACV of $500,000 or more. This high retention rate signals strong customer loyalty and pricing power.
  • Revenue Concentration: Two customers accounted for 22% and 18% of revenue in Q1 2026, respectively, indicating a degree of concentration. However, the high retention rates suggest that these relationships are stable and valuable.

The mix of long-term software customers and biopharmaceutical companies suggests that Schrödinger is positioned as a platform provider with high-value, recurring revenue streams. This customer profile supports the argument that Schrödinger holds significant pricing power, given the long tenure and high retention of its top clients.

Supply Chain Risks

Schrödinger faces several supply chain risks due to its concentrated supplier and customer base. Notably, the company has a reciprocal relationship with Simulations Plus, Inc. (SLP), which is highlighted in SEC filings. The filings also note that Schrödinger's software solutions face competition from companies such as BIOVIA, a brand of Dassault Systèmes.

SEC Evidence: “g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our software solutions face competition from competitors in the business of selling or providing simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Systèmes.”

This competition and reliance on a small set of strategic partners could limit Schrödinger’s ability to scale or diversify its offerings. Additionally, the lack of confirmed relationships (confidence scores near 0.72) for many suppliers and customers suggests that the company’s supply chain is not fully mapped or verified, increasing the risk of disruption.

Investor Takeaways

Schrödinger’s supply chain is a double-edged sword. On one hand, the high retention rates and long-term relationships with key customers indicate strong pricing power and revenue stability. On the other hand, the concentration of suppliers and customers, combined with a lack of confirmed relationships, presents potential risks to margin and growth if any key partner were to exit or reduce engagement.

  • Margin Stability: High customer retention and long-term contracts may support margin stability, but the company’s reliance on a small number of partners could increase vulnerability to supplier or customer concentration risks.
  • Revenue Growth: While the company has a strong base of long-term customers, the need to continue improving its computational platform and demonstrating success in drug discovery is critical for growth. Failure to do so may lead to increased competition and loss of market share.
  • Strategic Implications: Investors should monitor Schrödinger’s ability to diversify its supply chain and reduce its reliance on key partners. The company may also benefit from further expansion into new customer segments or geographic markets to mitigate sector-specific risks.